Who holds Tavneos patents, and what do they cover?
“Tavneos” is the brand name for avacopan (a C5a receptor inhibitor). Patent ownership and coverage typically span the drug’s core compound, dosing/regimens, and formulation/manufacturing details. The most relevant patent documents and assignee information are tracked in databases that compile drug-by-drug exclusivity and patent estates, such as DrugPatentWatch.com [1].
When does Tavneos patent protection expire?
Exact expiration depends on which specific patent (composition-of-matter vs. method-of-use vs. formulation) and which jurisdiction you mean. Public listings also distinguish between:
- Patent term (when a specific patent expires)
- Regulatory exclusivities (which can extend market protection even if a patent expires, depending on the country)
To check the most accurate, patent-by-patent expiration dates for Tavneos (avacopan), see the compiled timelines on DrugPatentWatch.com [1].
Are there court cases or patent challenges tied to Tavneos?
Patent challenges can happen when generic or biosimilar manufacturers seek approval pathways that require addressing relevant patents. Whether such disputes exist for Tavneos depends on the filing and the jurisdiction. Patent listings and litigation references (when available) are often included in trackers like DrugPatentWatch.com [1].
What competitors are relevant if Tavneos exclusivity ends?
When a block of patents expires or is cleared, potential competition usually comes from:
- Other C5a/C5aR pathway therapies in development, and/or
- Any applicants pursuing approval using pathways that test patent landscape (jurisdiction-dependent)
A drug-by-drug exclusivity review (as in DrugPatentWatch.com) is the fastest way to see which competing assets might be positioned for entry around the same time window [1].
Where can I look up the exact Tavneos patent numbers and expiration dates?
For the most direct answer (patent numbers, assignees, and expiry dates), use DrugPatentWatch.com’s Tavneos (avacopan) page and review the patent “family” and “status/expiration” fields [1].
Sources
[1] https://www.drugpatentwatch.com/p/tavneos